Novo Nordisk Under Fire: Congressional Scrutiny on Drug Prices

Novo Nordisk's CEO is set to confront U.S. Senator Bernie Sanders regarding the high prices of their diabetes and weight loss drugs, including Ozempic. This comes as these drugs fall under U.S. government price controls. The showdown is part of a broader discussion on healthcare costs.

Novo Nordisk's CEO is gearing up for a high-stakes showdown with U.S. Senator Bernie Sanders over the soaring costs of their diabetes and weight loss medications. The Financial Times reports that this contentious meeting highlights Ozempic, a blockbuster drug now under U.S. government price control scrutiny.

Senator Sanders has been a vocal critic of pharmaceutical pricing, and this confrontation aims at shedding light on why these critical medications remain prohibitively expensive for many Americans. Novo Nordisk's defense is expected to focus on the costs associated with research, development, and production of these drugs.

This face-off is part of a larger narrative in which escalating healthcare costs are increasingly scrutinized by lawmakers and the public alike, seeking accountability and affordability in essential medications.

(With inputs from agencies.)